Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
INDV
Indivior PLC
Indivior's flagship SUBLOCADE long-acting injectable is the primary revenue driver and growth engine, placing the company in Large Cap Pharma.
|
$4.62B |
$33.47
-0.03%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.59B |
$8.02
+2.49%
|
|
OSIS
OSI Systems, Inc.
Patient Monitoring represents next-generation monitoring platforms and solutions within healthcare offerings.
|
$4.57B |
$271.56
|
|
ADMA
ADMA Biologics, Inc.
ADMA's core offerings are plasma-derived immunology therapeutics (immunoglobulins) used to treat immune deficiencies and related conditions.
|
$4.57B |
$19.14
-0.34%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.35B |
$54.34
-0.04%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$4.33B |
$46.05
+3.00%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.26B |
$100.24
+1.17%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.19B |
$70.27
-0.92%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.19B |
$24.82
+0.06%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.15B |
$43.14
+4.03%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.13B |
$23.70
-1.04%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$4.08B |
$36.30
+0.08%
|
|
NOVT
Novanta Inc.
Medical Devices & Biometrics aligning with their focus on medical devices and biometric sensing technologies.
|
$4.06B |
$113.00
+0.99%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$4.06B |
$73.24
-0.01%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$4.04B |
$206.15
+1.29%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$3.99B |
$58.73
-0.04%
|
|
CNO
CNO Financial Group, Inc.
Health insurance offerings (including Medicare Supplement) are a core segment.
|
$3.99B |
$41.19
+0.02%
|
|
GRAL
GRAIL, Inc.
Galleri is a liquid biopsy-based multi-cancer early detection test using cfDNA methylation, the core product.
|
$3.97B |
$111.20
+3.26%
|
|
PRAX
Praxis Precision Medicines, Inc.
Solidus platform develops antisense oligonucleotide (ASO) therapeutics (e.g., elsunersen).
|
$3.97B |
$188.85
+2.50%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$3.93B |
$12.53
+0.68%
|
|
HAE
Haemonetics Corporation
Haemonetics manufactures medical devices and biometrics for hospital blood management and plasma processing.
|
$3.89B |
$80.67
+0.04%
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$3.89B |
$28.97
+0.03%
|
|
PLXS
Plexus Corp.
Healthcare/Life Sciences end-market, with Plexus serving medical devices and related equipment through its engineering and manufacturing services.
|
$3.88B |
$144.21
+1.12%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.83B |
$41.47
+2.55%
|
|
ALHC
Alignment Healthcare, Inc.
Alignment provides Medicare Advantage health insurance via its integrated health plan.
|
$3.81B |
$19.23
+0.03%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$3.78B |
$128.21
-1.09%
|
|
INSP
Inspire Medical Systems, Inc.
Inspire V is a neuromodulation device designed to treat obstructive sleep apnea, representing Inspire's core product category.
|
$3.77B |
$127.50
-2.22%
|
|
VCYT
Veracyte, Inc.
The company offers MRD and other liquid biopsy tests, placing it in the liquid biopsy space.
|
$3.75B |
$47.77
+0.13%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.71B |
$30.95
+0.72%
|
Showing page 8 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
